Study To Determine Safety/Efficacy of Lucentis For Treatment Of Retinal Angiomatous Proliferation Secondary To Age Related Macular Degeneration

NCT00395707 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

20

Enrollment

OTHER

Sponsor class

Conditions

Macular Degeneration

Interventions

DRUG: Lucentis
DRUG: Ranibizumab
DRUG: Ranibizumab (Lucentis)
DRUG: Ranibizumab (Lucentis)

Sponsor

The National Retina Institute

Collaborators

[object Object]